id: doi:10.18130/V3/F3TD5R
name: Cell Maps for Artificial Intelligence - June 2025 Data Release (Beta)
title: Cell Maps for Artificial Intelligence - June 2025 Data Release (Beta)
description: |-
  Description This dataset is the June 2025 Data Release of Cell Maps for Artificial Intelligence (CM4AI; CM4AI.org), the Functional Genomics Grand Challenge in the NIH Bridge2AI program. This Beta release includes perturb-seq data in undifferentiated KOLF2.1J iPSCs; SEC-MS data in undifferentiated KOLF2.1J iPSCs, iPSC-derived NPCs, neurons, cardiomyocytes, and treated and untreated MDA-MB468 breast cancer cells; and IF images in MDA-MB-468 breast cancer cells in the presence and absence of chemotherapy (vorinostat and paclitaxel).

  External Data Links
  Access external data resources related to this dataset:
  Sequence Read Archive (SRA) Data: NCBI BioProject
  Mass Spectrometry Data (Human iPSCs): MassIVE Repository
  Mass Spectrometry Data (Human Cancer Cells): MassIVE Repository

  Data Governance & Ethics
  Human Subjects: No
  De-identified Samples: Yes
  FDA Regulated: No
  Data Governance Committee: Jillian Parker (jillianparker@health.ucsd.edu)
  Ethical Review: Vardit Ravitsky (ravitskyv@thehastingscenter.org) and Jean-Christophe Belisle-Pipon (jean-christophe_belisle-pipon@sfu.ca)

  Completeness
  These data are not yet in completed final form:
  Some datasets are under temporary pre-publication embargo
  Protein-protein interaction (SEC-MS), protein localization (IF imaging), and CRISPRi perturbSeq data interrogate sets of proteins which incompletely overlap
  Computed cell maps not included in this release

  Maintenance Plan
  Dataset will be regularly updated and augmented through the end of the project in November 2026
  Updates on a quarterly basis
  Long term preservation in the University of Virginia Dataverse, supported by committed institutional funds

  Intended Use
  This dataset is intended for:
  AI-ready datasets to support research in functional genomics
  AI model training
  Cellular process analysis
  Cell architectural changes and interactions in presence of specific disease processes, treatment conditions, or genetic perturbations

  Limitations
  Researchers should be aware of inherent limitations:
  This is an interim release
  Does not contain predicted cell maps, which will be added in future releases
  The current release is most suitable for bioinformatics analysis of the individual datasets
  Requires domain expertise for meaningful analysis

  Prohibited Uses
  These laboratory data are not to be used in clinical decision-making or in any context involving patient care without appropriate regulatory oversight and approval

  Potential Sources of Bias
  Users should be aware of potential biases:
  Data in this release was derived from commercially available de-identified human cell lines
  Does not represent all biological variants which may be seen in the population at large
doi: doi:10.18130/V3/F3TD5R
issued: "2025-10-22"
version: June 2025 Beta
creators:
  - name: Clark T
  - name: Parker J
  - name: Al Manir S
  - name: Axelsson U
  - name: Ballllosero Navarro F
  - name: Chinn B
  - name: Churas CP
  - name: Dailamy A
  - name: Doctor Y
  - name: Fall J
  - name: Forget A
  - name: Gao J
  - name: Hansen JN
  - name: Hu M
  - name: Johannesson A
  - name: Khaliq H
  - name: Lee YH
  - name: Lenkiewicz J
  - name: Levinson MA
  - name: Marquez C
  - name: Metallo C
  - name: Muralidharan M
  - name: Nourreddine S
  - name: Niestroy J
  - name: Obernier K
  - name: Pan E
  - name: Polacco B
  - name: Pratt D
  - name: Qian G
  - name: Schaffer L
  - name: Sigaeva A
  - name: Thaker S
  - name: Zhang Y
  - name: BÃ©lisle-Pipon JC
  - name: Brandt C
  - name: Chen JY
  - name: Ding Y
  - name: Fodeh S
  - name: Krogan N
  - name: Lundberg E
  - name: Mali P
funders:
  - grantor:
      name: National Institutes of Health (NIH) Bridge2AI Program
purposes:
  - response: AI-ready datasets to support research in functional genomics
tasks:
  - response: AI model training
  - response: Cellular process analysis
  - response: Analysis of cell architectural changes and interactions under disease, treatment, or genetic perturbations
instances:
  - representation: Cell line assay data
    instance_type: Perturb-seq (CRISPRi) in undifferentiated KOLF2.1J iPSCs
    data_type: Sequencing-based single-cell perturbation readouts; primary data and/or intermediate processed data
    missing_information:
      - missing: Computed cell maps
        why_missing: Not included in this release; to be added in future releases
  - representation: Proteomics data
    instance_type: Size exclusion chromatography mass spectrometry (SEC-MS) in iPSCs, iPSC-derived NPCs, neurons, cardiomyocytes, and MDA-MB-468 cells (treated/untreated)
    data_type: Mass spectrometry raw and/or processed spectral/protein interaction data
  - representation: Imaging data
    instance_type: Immunofluorescence (IF) images in MDA-MB-468 cells with and without chemotherapy (vorinostat and paclitaxel)
    data_type: Microscopy image data
anomalies:
  - description:
      - Interim release; some datasets under temporary pre-publication embargo
      - Protein sets across modalities incompletely overlap
      - Computed cell maps not included
external_resources:
  - external_resources:
      - Sequence Read Archive (SRA) via NCBI BioProject
      - MassIVE Repository (Human iPSCs)
      - MassIVE Repository (Human Cancer Cells)
    restrictions:
      - External repositories may have their own licensing/terms of use
subpopulations:
  - identification:
      - Undifferentiated KOLF2.1J human iPSCs
      - iPSC-derived neural progenitor cells (NPCs)
      - iPSC-derived neurons
      - iPSC-derived cardiomyocytes
      - MDA-MB-468 human breast cancer cell line (treated and untreated)
collection_mechanisms:
  - description:
      - Perturb-seq (CRISPRi-based single-cell transcriptomics)
      - Size exclusion chromatography coupled mass spectrometry (SEC-MS)
      - Immunofluorescence microscopy imaging
acquisition_methods:
  - description:
      - Data directly observed via sequencing, proteomics, and imaging assays
    was_directly_observed: Yes
    was_reported_by_subjects: No
    was_inferred_derived: Some downstream computed cell maps are not included in this release
ethical_reviews:
  - description:
      - Ethical review oversight by Vardit Ravitsky (ravitskyv@thehastingscenter.org) and Jean-Christophe Belisle-Pipon (jean-christophe_belisle-pipon@sfu.ca)
deidentification:
  description:
    - Human Subjects: No
    - De-identified Samples: Yes
sensitive_elements:
  - description:
      - No patient-identifying information; data derived from de-identified human cell lines
future_use_impacts:
  - description:
      - Data derived from commercially available de-identified human cell lines; may not represent all biological variants
      - Interim release and modality coverage differences may impact integrative analyses
discouraged_uses:
  - description:
      - Not for clinical decision-making or patient care without appropriate regulatory oversight and approval
distribution_formats:
  - description:
      - University of Virginia Dataverse repository distribution
      - Links to external repositories (NCBI SRA/BioProject, MassIVE)
distribution_dates:
  - description:
      - "2025-10-22"
license_and_use_terms:
  - description:
      - Prohibited clinical use without appropriate regulatory oversight and approval
      - Some datasets subject to temporary pre-publication embargo
regulatory_restrictions:
  - description:
      - FDA Regulated: No
maintainers:
  - description:
      - Long-term preservation and hosting in the University of Virginia Dataverse (supported by institutional funds)
      - Data Governance Committee contact: Jillian Parker (jillianparker@health.ucsd.edu)
updates:
  description:
    - Dataset will be regularly updated and augmented through November 2026
    - Quarterly updates planned